Bortirel 2 Mg Injection

Product Description

BortiRel (bortezomib) for Injection is a proteasome inhibitor indicated for Multiple Myeloma part of combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation and for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for stem cell transplantation. BortiRel is also indicated for Mantle Cell Lymphoma for the treatment of patients with mantle cell lymphoma who have relapsed or were refractory to at least one prior therapy.

Effective Cancer Treatment

Bortirel 2 Mg Injection is recommended for treating multiple myeloma and mantle cell lymphoma in adults. Using Bortezomib as the active ingredient, this medication interferes with the growth of cancer cells and reduces tumor progression, contributing to improved patient outcomes.


Professional Administration Required

Bortirel should be administered only by qualified healthcare professionals. The injection can be given either intravenously or subcutaneously, following the precise dosage and frequency prescribed by the treating physician for optimal safety and effect.


Special Handling and Storage

To maintain its efficacy, Bortirel must be stored below 25C and protected from direct light. The medicine comes in a glass vial as a lyophilized powder that needs reconstitution before injection, ensuring each dose is prepared freshly for use in a clinical setting.